Alexander Seelenberger joined Aurus Capital in 2009, and is currently Managing Partner and responsible of leading their investment efforts through the first Chilean Healthcare-focused venture capital fund. He currently serves on the board of various portfolio companies, including Trigemina, Levita Magnetics, Algenis and Echopixel. Mr. Seelenberger has also served on the board of Asembio, the Chilean Biotechnology Association.

Prior to joining Aurus, Mr. Seelenberger worked for Athelera LLC, an M&A advisory boutique, based in New York City. Before that, he was a consultant for the Boston Consulting Group, where he developed a deep understanding of the pharmaceutical industry working for Big Pharma across Latin America.

Mr. Seelenberger has been a professor at the Universidad de Chile, teaching both undergraduate and graduate level courses at the University’s Faculty of Economics and Business. He holds an MBA from Harvard Business School, where he graduated as a Baker Scholar, and a Business Administration degree from the Universidad de Chile.